Maury Raycroft
Stock Analyst at Jefferies
(0.79)
# 1,619
Out of 4,650 analysts
50
Total ratings
22.22%
Success rate
-14.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $4.62 | +267.97% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $6.00 | +216.67% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $4.08 | +267.65% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $27.75 | +40.54% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $1.69 | +255.03% | 1 | Mar 13, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Upgrades: Buy | $4 → $46 | $16.20 | +183.95% | 1 | Mar 6, 2024 | |
| MGX Metagenomi | Initiates: Buy | $23 | $1.99 | +1,055.78% | 1 | Mar 5, 2024 | |
| TPST Tempest Therapeutics | Initiates: Buy | $15 | $1.10 | +1,263.64% | 1 | Feb 8, 2024 | |
| BCRX BioCryst Pharmaceuticals | Upgrades: Buy | $11 | $8.12 | +35.47% | 8 | Aug 4, 2023 | |
| ALLK Allakos | Upgrades: Buy | $6 → $9 | $1.22 | +637.70% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.70 | +370.59% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $42.97 | -86.04% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $19.98 | +275.38% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $284.69 | -18.51% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.68 | +93.66% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $16.91 | +59.67% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $2.22 | +125.46% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $15.91 | +201.70% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $5.99 | +501.00% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.69 | +1,745.34% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $48.94 | +251.45% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $0.93 | +2,158.06% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.86 | +1,543.36% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 → $40 | $3.35 | +1,094.03% | 5 | Aug 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $0.75 | +2,965.03% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $14.99 | +180.19% | 3 | Nov 1, 2017 |
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $4.62
Upside: +267.97%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $6.00
Upside: +216.67%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $4.08
Upside: +267.65%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $27.75
Upside: +40.54%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.69
Upside: +255.03%
Corbus Pharmaceuticals Holdings
Mar 6, 2024
Upgrades: Buy
Price Target: $4 → $46
Current: $16.20
Upside: +183.95%
Metagenomi
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.99
Upside: +1,055.78%
Tempest Therapeutics
Feb 8, 2024
Initiates: Buy
Price Target: $15
Current: $1.10
Upside: +1,263.64%
BioCryst Pharmaceuticals
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $8.12
Upside: +35.47%
Allakos
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $1.22
Upside: +637.70%
Jan 31, 2023
Initiates: Buy
Price Target: $8
Current: $1.70
Upside: +370.59%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $42.97
Upside: -86.04%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $19.98
Upside: +275.38%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $284.69
Upside: -18.51%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $5.68
Upside: +93.66%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $16.91
Upside: +59.67%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $2.22
Upside: +125.46%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $15.91
Upside: +201.70%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $5.99
Upside: +501.00%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.69
Upside: +1,745.34%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $48.94
Upside: +251.45%
Mar 31, 2021
Initiates: Buy
Price Target: $21
Current: $0.93
Upside: +2,158.06%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.86
Upside: +1,543.36%
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $3.35
Upside: +1,094.03%
Jul 16, 2018
Initiates: Buy
Price Target: $23
Current: $0.75
Upside: +2,965.03%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $14.99
Upside: +180.19%